Prana Biotechnology (PRAN)

[interestingtome]

PBT2 effects blood levels of soluble mHtt in early HD subjects.
Repost of an earlier thread started by Kad--

When discussing the PHAROS study in Vol 9 of HD insights, Dr Rosas made this comment.
"The study demonstrates that soluble mHTT can be usefully detected in blood, and that HD may influence its levels. Since then, we have used the same assay in blood from early HD subjects participating in HSG's Reach2HD trial of PBT2 (PRANA Biotechnology), and found that the treatment can affect soluble mHTT levels. Currently we are developing an assay that can measure mHTT aggregates in clinical samples, which we believe will also prove useful for developing treatments that target Huntingtin."

That is a nice little biomarker clearly showing PBT target engagement with the disease. It is nice to see considering it was in the early stage patients PBT2 was stat sig over all Z scores.